Holen Sie sich die Stockscreener-App
17.68
2.88%
0.4942
Schlusskurs vom Vortag:
$17.19
Offen:
$17.5
24-Stunden-Volumen:
14,813
Relative Volume:
0.06
Marktkapitalisierung:
$797.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+5.46%
1M Leistung:
-6.18%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.16
$17.90
1-Wochen-Bereich:
$15.78
$17.90
52-Wochen-Spanne:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MPLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
17.57 | 779.96M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.91 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.66 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.96 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight updates trial timelines and highlights CNS pipeline - TipRanks
MapLight Therapeutics accelerates timeline for Phase 2 trial results By Investing.com - Investing.com India
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewswire Inc.
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com Nigeria
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
MapLight2025 Funding Rounds & List of Investors - Tracxn
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com
SandboxAQ and MapLight join forces on CNS - The Pharma Letter
6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace
SandboxAQ and MapLight Therapeutics Partner on Novel CNS Therapies - HPCwire
SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria
SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com
MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times
Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Es liegen keine Finanzdaten für Maplight Therapeutics Inc (MPLT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Maplight Therapeutics Inc-Aktie (MPLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 10% Owner |
Oct 28 '25 |
Buy |
17.00 |
5,441,176 |
92,499,992 |
19,697,464 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):